Company: ARWR
Filing Date: 2025-05-12
Form Type: 10-Q
Source: 0001628280-25-024666
Chunk: 83

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-05-12
Form: 10-Q
Item: Part I, Item 8
Chunk 83
---
ized LossesFair ValueAvailable-for-sale securities$910,744 $1,063 $(107)$911,700 Total current investments$910,744 $1,063 $(107)$911,700 As of September 30, 2024(in thousands)Adjusted BasisGrossUnrealized GainsGrossUnrealized LossesFair ValueAvailable-for-sale securities$577,465 $837 $(26)$578,276 Total current investments$577,465 $837 $(26)$578,276 The following table summarizes the contract maturity of the available-for-sale securities as of:   March 31, 2025September 30, 2024(in thousands)Within one year$422,082 $578,276 After one to two years301,085 — After two to three years188,533 — Total$911,700 $578,276 

As of March 31, 2025 and September 30, 2024, the gross unrealized losses were immaterial. The Company has determined that the available-for-sale securities that were in an unrealized loss position did not have any credit loss impairment as of March 31, 2025 and 2024. 

12

NOTE 5. INTANGIBLE ASSETS

Intangible assets subject to amortization include patents and a license agreement capitalized as part of the Novartis RNAi asset acquisition in March 2015. The following table presents the components of intangible assets: Gross Carrying AmountAccumulated AmortizationImpairmentNet Carrying AmountUseful Lives(in thousands)(in years)As of March 31, 2025Patents$21,728 $15,649 $— $6,079 14License3,129 1,497 — 1,632 21Total intangible assets, net$24,857 $17,146 $— $7,711 As of September 30, 2024Patents$21,728 $14,873 $— $6,855 14License3,129 1,422 — 1,707 21Total intangible assets, net$24,857 $16,295 $— $8,562 Intangible assets are reviewed annually for impairment and more frequently if potential impairment indicators exist. No impairment indicators were identified during the six months ended March 31,